FDA delays high-stakes decision on muscular dystrophy drug
WASHINGTON - Federal health regulators will take more time to review a highly-contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
Drugmaker Sarepta Therapeutics Inc. said the Food and Drug Administration will miss its goal of issuing a decision on the drug by Thursday. While the FDA does not comment on such delays, the extended timeline raises the possibility that regulators may ultimately approve the company's medication.
Company shares rocketed 16 percent higher in morning trading.
Sarepta's drug eteplirsen has become rallying point for patients and families stricken by the deadly inherited disease, which causes muscle weakness and eventually the loss of all basic movement. The disease affects one of every 3,600 boys worldwide and usually causes death by age 25.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Mass vaccine site opens again Tuesday, April 20
Baton Rouge rapper to appear in court today
String of car break-ins in luxury Baton Rouge apartment complex
LSU announces that students will not be required to get COVID-19 vaccines
Coast Guard suspends search for Seacor Power crew, volunteer diver weighs in...
Legendary Parkview coach Kenny Guillot passes away at 76
Southern Wins Third Straight Bayou Classic
White squad edges Purple in LSU Spring game
'We have a plan': Coach O quiet on how Title IX scandal...
Southeastern regains sole possession of first place in Southland standings with win...